# US 2019/0315732 A1 · Modulators of proteolysis and associated methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315732 A1
- Document ID: US20190315732A1
- Status: Published application
- Kind: A1
- Application number: 16/375,643
- Filed: 2019-04-04
- Published: 2019-10-17
- Earliest claimed: 2018-04-04
- Assignees: Arvinas Operations, Inc.
- Applicants: Arvinas Operations, Inc.; Yale University
- Inventors: Andrew P. Crew; Keith R. Hornberger; Jing Wang; Hanging Dong; Michael Berlin; Craig M. Crews
- Web page: https://patentgrep.com/patent/US20190315732A1

## CPC

- C07D 417/14: containing three or more hetero rings
- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to bifunctional compounds, which find utility as modulators of Kirsten rat sarcoma protein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

## Claims

### Claim 1

A bifunctional compound having the chemical structure:
ULM-L-PTM,
or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph or prodrug thereof,
wherein:
the ULM is a small molecule E3 ubiquitin ligase binding moiety that binds an E3 ubiquitin ligase;
the PTM is a small molecule comprising a Kirsten rat sarcoma protein (KRas) targeting moiety; and
the L is a bond or a chemical linking moiety connecting the ULM and the PTM.

### Claim 2 (depends on 1)

The bifunctional compound according to claim 1, wherein the E3 ubiquitin ligase binding moiety that targets an E3 ubiquitin ligase selected from the group consisting of Von Hippel-Lindau (VLM), cereblon (CLM), mouse double-minute homolog 2 (MLM), and IAP (ILM).

### Claim 3 (depends on 1)

The bifunctional compound according to claim 1, wherein PTM is represented by:
wherein:
is an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;
XPTM is C or N;
WPTM is chosen from the group consisting of optionally substituted C3-C6 cycloalkyl, and optionally substituted C3-C6 heteroalkyl, optionally substituted C3-C6 heterocycloalkyl, optionally substituted aryl (e.g., optionally substituted C5-C7 aryl), optionally substituted heteroaryl (e.g., optionally substituted C5-C7 heteroaryl);
RPTM1A is NRPTM9RPTM10, ORPTM9RPTM10, H, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted C3-C6 cycloalkyl, optionally substituted O—(C3-C6 cycloalkyl), optionally substituted —O—C1-4 alkyl-C3-6cycloalkyl, optionally substituted C3-C6 heteroalkyl, optionally substituted O—(C3-C6 heteroalkyl), optionally substituted O—C1-4 alkyl-C3-6 heteroalkyl, optionally substituted O—C1-4 alkyl-C3-6 heterocycloalkyl, optionally substituted aryl (e.g., optionally substituted C5-C7 aryl), optionally substituted O-aryl (e.g., optionally substituted O—(C5-C7 aryl)), optionally substituted heteroaryl (e.g., optionally substituted C5-C7 heteroaryl), optionally substituted O-heteroaryl (e.g., optionally substituted O—(C5-C7 heteroaryl)), optionally substituted
(e.g., optionally substituted with at least one alkyl, such as the * carbon may be optionally substituted with an alkyl), optionally substituted
optionally substituted
optionally substituted
optionally substituted
optionally substituted
optionally substituted
optionally substituted
optionally substituted
optionally substituted
optionally substituted
optionally substituted
optionally substituted
(e.g., optionally substituted with at least one alkyl, such as the * carbon may be optionally substituted with an alkyl), optionally substituted
(e.g., optionally substituted with at least one alkyl, such as the * carbon may be optionally substituted with an alkyl), optionally substituted
(e.g., optionally substituted with at least one alkyl, such as the * carbon may be optionally substituted with an alkyl), optionally substituted
(e.g., optionally substituted with at least one alkyl, such as the * carbon may be optionally substituted with an alkyl), optionally substituted
(e.g., optionally substituted with at least one alkyl, such as the * carbon may be optionally substituted with an alkyl), optionally substituted
(e.g., optionally substituted with at least one alkyl, such as the * carbon may be optionally substituted with an alkyl), wherein N* is a N atom of a heterocycloalkyl of the linker (L);
RPTM1B is NRPTM9RPTM10, ORPTM9RPTM10, H, optionally substituted alkyl, optionally substituted O-alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted O—(C3-C6 cycloalkyl), optionally substituted —O—C1-4 alkyl-C3-6cycloalkyl, optionally substituted C3-C6 heteroalkyl, optionally substituted O—(C3-C6 heteroalkyl), optionally substituted O—C1-4 alkyl-C3-6 heteroalkyl, optionally substituted aryl (e.g., optionally substituted C5-C7 aryl), optionally substituted O-aryl (e.g., optionally substituted O—(C5-C7 aryl)), optionally substituted heteroaryl (e.g., optionally substituted C5-C7 heteroaryl), optionally substituted O-heteroaryl (e.g., optionally substituted O(C5-C7 heteroaryl)), optionally substituted
(e.g., optionally substituted with at least one alkyl, such as the * carbon may be optionally substituted with an alkyl), optionally substituted
optionally substituted
optionally substituted
optionally substituted
optionally substituted
optionally substituted
optionally substituted
optionally substituted
RPTM9 and RPTM10 are each independently H, optionally substituted C1-C6 alkyl, optionally substituted aliphatic amine, optionally substituted aliphatic amide;
RPTM2 is H, (C═O)RPTM2′, optionally substituted linear or branched alkyl;
RPTM2′ is optionally substituted linear or branched alkyl, optionally substituted alkene, —N(RPTM8)2, or —C(OH)2;
RPTM3 is alkyl, alkoxy, phenyl, or napthalene, each independently substituted with OH, H, halogen;
RPTM4A is OH, H, or halogen, optionally substituted linear or branched C1-C6 alkyl;
RPTM4B is OH, H, —CH2CN, halogen, optionally substituted linear or branched C1-C6 alkyl;
RPTM5 is chosen from the group consisting of optionally substituted aryl, optionally substituted biaryl, optionally substituted heteroaryl, optionally substituted biheteroaryl, optionally substituted C3-C6 cycloalkyl, optionally substituted C3-C6 cycloheteroalkyl, halogen, H, optionally substituted linear or branched alkyl (e.g., optionally substituted linear or branched C1-C6 alkyl), OH, and alkoxy;
RPTM8 is a H or an alkyl (e.g, a C1 alkyl, a C2 alkyl, a C3 alkyl, or a C4 alkyl);
t is 0, 1, 2, 3, 4, 5, 6; and
the indicates the site of attachment of at least one of a linker, ULM, ULM′, CLM, CLM′, VLM, VLM′, ILM, ILM′, MLM, MLM′, or a combination thereof.

### Claim 4 (depends on 3)

The bifunctional compound according to claim 3, wherein the PTM is represented by:
wherein:
XPTM1 is NH or O;
RPTM6 is aryl, heteroaryl,
wherein N* a N atom of a heterocycloalkyl (e.g., a C4-C8 heterocycloalkyl) of the linker (L);
RPTM7 is H, aryl, O-aryl, heteroaryl, O-heteroaryl,
RPTM9 is H, optionally substituted C1-C6 alkyl, optionally substituted aliphatic amine, optionally substituted aliphatic amide optionally substituted
(e.g., optionally substituted with at least one alkyl, such as the * carbon may be optionally substituted with an alkyl);
the can be a single bond or a double bond; and
the indicates the site of attachment of at least one of a linker, ULM, ULM′, CLM, CLM′, VLM, VLM′, ILM, ILM′, MLM, MLM′, or a combination thereof.

### Claim 5 (depends on 3)

The bifunctional compound according to claim 3, wherein the PTM is represented by chemical structure:

### Claim 6 (depends on 1)

The bifunctional compound according to claim 1, wherein ULM is a Von Hippel-Lindau (VHL) ligase-binding moiety (VLM) with a chemical structure represented by:
wherein:
X1, X2 are each independently selected from the group of a bond, O, NRY3, CRY3RY4, C═O, C═S, SO, and SO2;
RY3, RY4 are each independently selected from the group of H, linear or branched C1-6 alkyl, optionally substituted by 1 or more halo, C1-6 alkoxyl optionally substituted by 0-3 RPgroups;
RP is 0, 1, 2, or 3 groups independently selected from the group H, halo, —OH, C1-3 alkyl, C═O;
W3 is selected from the group of an optionally substituted T, an optionally substituted -T-N(R1aR1b)X3, an optionally substituted -T-N(R1aR1b), an optionally substituted -T-Aryl, an optionally substituted -T-Heteroaryl, an optionally substituted T-biheteroaryl, an optionally substituted -T-heterocyclyl, an optionally substituted -T-bieterocyclyl, an optionally substituted —NR1-T-Aryl, an optionally substituted —NR1-T-Heteroaryl or an optionally substituted —NR1-T-heterocyclyl;
X3 is C═O, R1, R1a, R1b;
each of R1, R1a, R1b is independently selected from the group consisting of H, linear or branched C1-C6 alkyl group optionally substituted by 1 or more halo or —OH groups, RY3C═O, RY3C═S, RY3SO, RY3SO2, N(RY3RY4)C═O, N(RY3RY4)C═S, N(RY3RY4)SO, and N(RY3RY4)SO2;
T is selected from the group of an optionally substituted alkyl, —(CH2)n— group, wherein each one of the methylene groups is optionally substituted with one or two substituents selected from the group of halogen, methyl, optionally substituted alkoxy, a linear or branched C1-C6 alkyl group optionally substituted by 1 or more halogen, C(O) NR1R1a, or NR1R1a or R1 and R1a are joined to form an optionally substituted heterocyclyl, or —OH groups or an amino acid side chain optionally substituted; and
n is 0 to 6,
W4 is
R14a, R14b, are each independently selected from the group of H, haloalkyl, or optionally substituted alkyl;
W5 is selected from the group of an optionally substituted phenyl or an optionally substituted 5-10 membered heteroaryl;
R15 is selected from the group of H, halogen, CN, OH, NO2, NR14aR14b, OR14a, CONR14aR14b, NR14aCOR14b, SO2NR14aR14b, NR14a SO2R14b, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloheteroalkyl;
and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM′) or a chemical linker moiety coupling at least one PTM or a ULM′ or both to ULM.

### Claim 7 (depends on 1)

The bifunctional compound according to claim 1, wherein ULM is a Von Hippel-Lindau (VHL) ligase-binding moiety (VLM) with a chemical structure represented by:
wherein:
W3 is selected from the group of an optionally substituted aryl, optionally substituted heteroaryl, or
R9 and R10 are independently hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl, or haloalkyl, or R9, R10, and the carbon atom to which they are attached form an optionally substituted cycloalkyl;
R11 is selected from the group of an optionally substituted heterocyclyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted aryl,
R12 is selected from the group of H or optionally substituted alkyl;
R13 is selected from the group of H, optionally substituted alkyl, optionally substituted alkylcarbonyl, optionally substituted (cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted (heterocyclyl)carbonyl, or optionally substituted aralkyl;
R14a, R14b, are each independently selected from the group of H, haloalkyl, or optionally substituted alkyl;
W5 is selected from the group of an optionally substituted phenyl or an optionally substituted 5-10 membered heteroaryl;
R15 is selected from the group of H, halogen, CN, OH, NO2, NR14aR14b, OR14a, CONR14aR14b, NR14aCOR14b, SO2NR14aR14b, NR14a SO2R14b, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloheteroalkyl;
each R16 is independently selected from the group of halo, CN, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted alkoxy, hydroxy, or optionally substituted haloalkoxy;
o is 0, 1, 2, 3, or 4;
R18 is independently selected from the group of halo, optionally substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl, haloalkoxy or a linker; and
p is 0, 1, 2, 3, or 4, and wherein the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM′) or a chemical linker moiety coupling at least one PTM or a ULM′ or both to ULM.

### Claim 8 (depends on 6)

The bifunctional compound according to claim 6, wherein the ULM has a chemical structure selected from the group of:
wherein:
R1 is H, ethyl, isopropyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl; optionally substituted alkyl, optionally substituted hydroxyalkyl, optionally substituted heteroaryl, or haloalkyl;
R14a is H, haloalkyl, optionally substituted alkyl, methyl, fluoromethyl, hydroxymethyl, ethyl, isopropyl, or cyclopropyl;
R15 is selected from the group consisting of H, halogen, CN, OH, NO2, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted alkyl, optionally substituted haloalkyl, optionally substituted haloalkoxy, optionally substituted cycloalkyl, or optionally substituted cycloheteroalkyl;
X is C, CH2, or C═O
R3 is absent or an optionally substituted 5 or 6 membered heteroaryl; and
wherein the dashed line indicates the site of attachment of at least one PTM, another ULM (ULM′) or a chemical linker moiety coupling at least one PTM or a ULM′ or both to the ULM.

### Claim 9 (depends on 1)

The bifunctional compound according to claim 1, wherein the ULM comprises a group according to the chemical structure:
wherein:
R1′ of ULM-g is an optionally substituted C1-C6 alkyl group, an optionally substituted —(CH2)nOH, an optionally substituted —(CH2)nSH, an optionally substituted (CH2)n—O—(C1-C6)alkyl group, an optionally substituted (CH2)n—WCOCW—(C0-C6)alkyl group containing an epoxide moiety WCOCW where each W is independently H or a C1-C3 alkyl group, an optionally substituted —(CH2)nCOOH, an optionally substituted —(CH2)nC(O)—(C1-C6 alkyl), an optionally substituted —(CH2)nNHC(O)—R1, an optionally substituted —(CH2)nC(O)—NR1R2, an optionally substituted —(CH2)nOC(O)—NR1R2, —(CH2O)nH, an optionally substituted —(CH2)nOC(O)—(C1-C6 alkyl), an optionally substituted —(CH2)nC(O)—O—(C1-C6 alkyl), an optionally substituted —(CH2O)nCOOH, an optionally substituted —(OCH2)nO—(C1-C6 alkyl), an optionally substituted —(CH2O)nC(O)—(C1-C6 alkyl), an optionally substituted —(OCH2)nNHC(O)—R1, an optionally substituted —(CH2O)nC(O)—NR1R2, —(CH2CH2O)nH, an optionally substituted —(CH2CH2O)nCOOH, an optionally substituted —(OCH2CH2)nO—(C1-C6 alkyl), an optionally substituted —(CH2CH2O)nC(O)—(C1-C6 alkyl), an optionally substituted —(OCH2CH2)nNHC(O)—R1, an optionally substituted —(CH2CH2O)nC(O)—NR1R2, an optionally substituted —SO2RS, an optionally substituted S(O)RS, NO2, CN or halogen (F, Cl, Br, I, preferably F or Cl);
R1 and R2 of ULM-g are each independently H or a C1-C6 alkyl group which may be optionally substituted with one or two hydroxyl groups or up to three halogen groups (preferably fluorine);
RS of ULM-g is a C1-C6 alkyl group, an optionally substituted aryl, heteroaryl or heterocycle group or a —(CH2)mNR1R2 group;
X and X′ of ULM-g are each independently C═O, C═S, —S(O), S(O)2, (preferably X and X′ are both C═O);
R2′ of ULM-g is an optionally substituted —(CH2)n—(C═O)u(NR1)v(SO2)walkyl group, an optionally substituted —(CH2)n—(C═O)u(NR1)v(SO2)wNR1NR2N group, an optionally substituted —(CH2)n—(C═O)u(NR1)v(SO2)w-Aryl, an optionally substituted —(CH2)n—(C═O)u(NR1)v(SO2)w-Heteroaryl, an optionally substituted —(CH2)n—(C═O)vNR1(SO2)w-Heterocycle, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w-alkyl, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w— NR1NR2N, an optionally substituted —NR1—(CH2)n—C(O)(NR1)v(SO2)w—NR1C(O)R1N, an optionally substituted —NR1—(CH2)n—(C═O)u(NR1)v(SO2)w-Aryl, an optionally substituted —NR1—(CH2)-Aryl-Heteroaryl, an optionally substituted —NR1—(CH2)n—(C═O)u(NR1)v(SO2)w-Heteroaryl or an optionally substituted —NR1—(CH2)n—(C═O)vNR1(SO2)w-Heterocycle, an optionally substituted —XR2′-alkyl group; an optionally substituted —XR2′-Aryl group; an optionally substituted —XR2′-Heteroaryl group; an optionally substituted —XR2′-Heterocycle group; an optionally substituted;
R3′ of ULM-g is an optionally substituted alkyl, an optionally substituted —(CH2)n—(O)u(NR1)v(SO2)w-alkyl, an optionally substituted —(CH2)n—C(O)u(NR1)v(SO2)w—NR1NR2N, an optionally substituted —(CH2)n—C(O)u(NR1)v(SO2)w—NR1C(O)R1N, an optionally substituted —(CH2)n—C(O)u(NR1)v(SO2)w—C(O)NR1R2, an optionally substituted —(CH2)n—C(O)u(NR1)v(SO2)w-Aryl, an optionally substituted —(CH2)n—C(O)u(NR1)v(SO2)w-Heteroaryl, an optionally substituted —(CH2)n—C(O)u(NR1)v(SO2)w-Heterocycle, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w-alkyl, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w— NR1NR2N, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w—NR1C(O)R1N, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w-Aryl, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w-Heteroaryl, an optionally substituted —NR1—(CH2)n—C(O)u(NR1)v(SO2)w-Heterocycle, an optionally substituted —O—(CH2)n—(C═O)u(NR1)v(SO2)w-alkyl, an optionally substituted —O—(CH2)n-(C═O)u(NR1)v(SO2)w—NR1NR2N, an optionally substituted —O—(CH2)n-(C═O)u(NR1)v(SO2)w—NR1C(O)R1N, an optionally substituted —O—(CH2)n-(C═O)u(NR1)v(SO2)w-Aryl, an optionally substituted —O—(CH2)n—(C═O)u(NR1)v(SO2)w-Heteroaryl or an optionally substituted —O—(CH2)n—(C═O)u(NR1)v(SO2)w-Heterocycle; —(CH2)n—(V)n′—(CH2)n—(V)n′-alkyl group, an optionally substituted —(CH2)n—(V)n′—(CH2)n—(V)n′-Aryl group, an optionally substituted —(CH2)n—(V)n′—(CH2)n—(V)n′-Heteroaryl group, an optionally substituted —(CH2)n—(V)n′—(CH2)n—(V)n′-Heterocycle group, an optionally substituted —(CH2)n—N(R1′)(C═O)m′—(V)n′-alkyl group, an optionally substituted —(CH2)n—N(R1′)(C═O)m′—(V)n′-Aryl group, an optionally substituted —(CH2)n—N(R1′)(C═O)m′—(V)n′-Heteroaryl group, an optionally substituted —(CH2)n—N(R1′)(C═O)m′—(V)n′-Heterocycle group, an optionally substituted —XR3′-alkyl group; an optionally substituted —XR3′-Aryl group; an optionally substituted —XR3′-Heteroaryl group; an optionally substituted —XR3′-Heterocycle group; an optionally substituted;
R1N and R2N of ULM-g are each independently H, C1-C6 alkyl which is optionally substituted with one or two hydroxyl groups and up to three halogen groups or an optionally substituted —(CH2)n-Aryl, —(CH2)n-Heteroaryl or —(CH2)n-Heterocycle group;
V of ULM-g is O, S or NR1;
R1 of ULM-g is the same as above;
R1 and R1′ of ULM-g are each independently H or a C1-C3 alkyl group;
XR2′ and XR3′ of ULM-g are each independently an optionally substituted —CH2)n—, —CH2)n—CH(Xv)═CH(Xv)-(cis or trans), —CH2)n—CH≡CH—, —(CH2CH2O)n— or a C3-C6 cycloalkyl group, where Xv is H, a halo or a C1-C3 alkyl group which is optionally substituted;
each m of ULM-g is independently 0, 1, 2, 3, 4, 5, 6;
each m′ of ULM-g is independently 0 or 1;
each n of ULM-g is independently 0, 1, 2, 3, 4, 5, 6;
each n′ of ULM-g is independently 0 or 1;
each u of ULM-g is independently 0 or 1;
each v of ULM-g is independently 0 or 1;
each w of ULM-g is independently 0 or 1; and
any one or more of R1′, R2′, R3′, X and X′ of ULM-g is optionally modified to be covalently bonded to the PTM group through a linker group when PTM is not ULM′, or when PTM is ULM′, any one or more of R1′, R2′, R3′, X and X′ of each of ULM and ULM′ are optionally modified to be covalently bonded to each other directly or through a linker group, or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.

### Claim 10 (depends on 1)

The bifunctional compound according to claim 1, wherein the ULM is a cereblon E3 ligase-binding moiety (CLM) selected from the group consisting of a thalidomide, lenalidomide, pomalidomide, analogs thereof, isosteres thereof, or derivatives thereof.

### Claim 11 (depends on 10)

The bifunctional compound according to claim 10, wherein the CLM has a chemical structure represented by:
wherein:
W is selected from the group consisting of CH2, CHR, C═O, SO2, NH, and N-alkyl;
each X is independently selected from the group consisting of O, S, and H2;
Y is selected from the group consisting of CH2, —C═CR′, NH, N-alkyl, N-aryl, N-hetaryl, N-cycloalkyl, N-heterocyclyl, O, and S;
Z is selected from the group consisting of O, S, and H2;
G and G′ are independently selected from the group consisting of H, optionally substituted linear or branched alkyl, OH, R′OCOOR, R′OCONRR″, CH2-heterocyclyl optionally substituted with R′, and benzyl optionally substituted with R′;
Q1, Q2, Q3, and Q4 represent a carbon C substituted with a group independently selected from R′, N or N-oxide;
A is independently selected from the group H, optionally substituted linear or branched alkyl, cycloalkyl, C1 and F;
R comprises —CONR′R″, —OR′, —NR′R″, —SR′, —SO2R′, —SO2NR′R″, —CR′R″—, —CR′NR′R″—, (—CR′O)n′R″, -aryl, -hetaryl, optionally substituted linear or branched alkyl, -cycloalkyl, -heterocyclyl, —P(O)(OR′)R″, —P(O)R′R″, —OP(O)(OR′)R″, —OP(O)R′R″, —Cl, —F, —Br, —I, —CF3, —CN, —NR′SO2NR′R″, —NR′CONR′R″, —CONR′COR″, —NR′C(═N—CN)NR′R″, —C(═N—CN)NR′R″, —NR′C(═N—CN)R″, —NR′C(═C—NO2)NR′R″, —SO2NR′COR″, —NO2, —CO2R′, —C(C═N—OR′)R″, —CR′═CR′R″, —CCR′, —S(C═O)(C═N—R′)R″, —SF5 and —OCF3;
R′ and R″ are independently selected from the group consisting of a bond, H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclic, —C(═O)R, heterocyclyl, each of which is optionally substituted;
n′ is an integer from 1-10;
represents a bond that may be stereospecific ((R) or (S)) or non-stereospecific; and
Rn comprises from 1 to 4 independently selected functional groups or atoms, for example, O, OH, N, C1-C6 alkyl, C1-C6 alkoxy, -alkyl-aryl (e.g., an -alkyl-aryl comprising at least one of C1-C6 alkyl, C4-C7 aryl, or a combination thereof), aryl (e.g., C5-C7 aryl), amine, amide, or carboxy,
wherein:
when n is 1, Rn is modified to be covalently joined to the linker group (L), and
when n is 2, 3, or 4, then one Rn is modified to be covalently joined to the linker group (L), and any other Rn is optionally modified to be covalently joined to a PTM, a CLM, a second CLM having the same chemical structure as the CLM, a CLM′, a second linker, or any multiple or combination thereof.

### Claim 12 (depends on 10)

The bifunctional compound according to claim 10, wherein the CLM has a chemical structure represented by:
wherein:
W is independently selected from CH2, CHR, C═O, SO2, NH, and N-alkyl;
Q1, Q2, Q3, Q4, Q5 are each independently a carbon C or N substituted with a group independently selected from R′, N or N-oxide;
R1 is selected from absent, H, OH, CN, C1-C3 alkyl, C═O;
R2 is selected from the group absent, H, OH, CN, C1-C3 alkyl, CHF2, CF3, CHO, C(═O)NH2;
R3 is selected from H, alkyl (e.g., C1-C6 or C1-C3 alkyl), substituted alkyl (e.g., substituted C1-C6 or C1-C3 alkyl), alkoxy (e.g., C1-C6 or C1-C3 alkoxyl), substituted alkoxy (e.g., substituted C1-C6 or C1-C3 alkoxyl);
R4 is selected from H, alkyl, substituted alkyl;
R5 and R6 are each independently H, halogen, C(═O)R′, CN, OH, CF3;
X is C, CH, C═O, or N;
X1 is C═O, N, CH, or CH2;
R′ is selected from H, halogen, amine, alkyl (e.g., C1-C3 alkyl), substituted alkyl (e.g., substituted C1-C3 alkyl), alkoxy (e.g., C1-C3 alkoxyl), substituted alkoxy (e.g., substituted C1-C3 alkoxyl), NR2R3, C(═O)OR2, optionally substituted phenyl;
n is 0-4;
is a single or double bond; and
the CLM is covalently joined to a PTM, a chemical linker group (L), a ULM, CLM, CLM′, or combinations thereof.

### Claim 13 (depends on 1)

The bifunctional compound according to claim 1, wherein the ULM is a (MDM2) binding moiety (MLM) with a chemical moiety selected from the group consisting of a substituted imidazolines, a substituted spiro-indolinones, a substituted pyrrolidines, a substituted piperidinones, a substituted morpholinones, a substituted pyrrolopyrimidines, a substituted imidazolopyridines, a substituted thiazoloimidazoline, a substituted pyrrolopyrrolidinones, and a substituted isoquinolinones.

### Claim 14 (depends on 13)

The bifunctional compound associating to claim 13, wherein the MLM is selected from:
wherein:
R1′ and R2′ of Formulas A-1-1 through A-1-4 (i.e., A-1-1, A-1-2, A-1-3, and A-1-4) are independently selected from the group consisting of F, Cl, Br, I, acetylene, CN, CF3 and NO2;
R3′ is selected from the group consisting of —OCH3, —OCH2CH3, —OCH2CH2F, —OCH2CH2OCH3, and —OCH(CH3)2;
R4′ of Formulas A-1-1 through A-1-4 is selected from the group consisting of H, halogen, —CH3, —CF3, —OCH3, —C(CH3)3, —CH(CH3)2, -cyclopropyl, —CN, —C(CH3)2OH, —C(CH3)2OOCH2CH3, —C(CH3)2CH2OH, —C(CH3)2CH2OCH2CH3, C(CH3)2CH2OCH2CH2OH, —C(CH3)2CH2OCH2CH3, —C(CH3)2CN, —C(CH3)2C(O)CH3, —C(CH3)2C(O)NHCH3, —C(CH3)2C(O)N(CH3)2, —SCH3, —SCH2CH3, —S(O)2CH3, S(O2)CH2CH3, —NHC(CH3)3, —N(CH3)2, pyrrolidinyl, and 4-morpholinyl;
R5′ of Formulas A-1-1 through A-1-4 is selected from the group consisting of halogen, -cyclopropyl, —S(O)2CH3, —S(O)2CH2CH3, 1-pyrrolidinyl, —NH2, —N(CH3)2, and —NHC(CH3)3; and
R6′ of Formulas A-1-1 through A-1-4 is selected from H,
wherein the linker is attached to the “*” of R6′or to the terminal atom of R4′;
R7′ of Formula A-4-1 through A-4-6 is one or more (e.g., 1, 2, 3, 4) halogens;
R8′ of Formula A-4-1 through A-4-6 is one or more groups (e.g., 1, 2, 3, or 4 groups) selected from the group consisting of H, —F, —Cl, —Br, —I, —CN, —NO2, ethylnyl, cyclopropyl, methyl, ethyl, isopropyl, vinyl, methoxy, ethoxy, isopropoxy, —OH, other C1-6 alkyl, other C1-6 alkenyl, and C1-6 alkynyl, mono-, di- or tri-substituted;
R9′ of Formula A-4-1 through A-4-6 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, hetero aryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, alkenyl, and substituted cycloalkenyl;
Z of Formula A-4-1 through A-4-6 is selected from the group consisting of H, —OCH3, —OCH2CH3, and halogen;
R10′ and R11′ of Formula A-4-1 through A-4-6 are each independently selected from the group consisting of H, (CH2)n—R′, (CH2)n—NR′R″, (CH2)n—NR′COR″, (CH2)n—NR′SO2R″, (CH2)n—COOH, (CH2)n—COOR′, (CH)n—CONR′R″, (CH2)n—OR′, (CH2)n—SR′, (CH2)n—SOR′, (CH2)n—CH(OH)—R′, (CH2)n—COR′, (CH2)n—SO2R′, (CH2)n—SONR′R″, (CH2)n—SO2NR′R″, (CH2CH2O)m—(CH2)n—R′, (CH2CH2O)m—(CH2)n—OH, (CH2CH2O)m—(CH2)n—OR′, (CH2CH2O)m—(CH2)n—NR′R″, (CH2CH2O)m—(CH2)n—NR′COR″, (CH2CH2O)m(CH2)n—NR′SO2R″, (CH2CH2O)m(CH2)n—COOH, (CH2CH2O)m(CH2)n—COOR′, (CH2CH2O)m (CH2)n—CONR′R″, (CH2CH2O)m—(CH2)n—SO2R′, (CH2CH2O)m—(CH2)n—COR′, (CH2CH2O)m—(CH2)n—SONR′R″, (CH2CH2O)m—(CH2)n—SO2NR′R″, (CH2)p—(CH2CH2O)m—(CH2)nR′, (CH2)p—(CH2CH2O)m—(CH2)n—OH, (CH2)p—(CH2CH2O)m—(CH2)n—OR′, (CH2)p—(CH2CH2O)m—(CH2)n—NR′R″, (CH2)p—(CH2CH2O)m—(CH2)n—NR′COR″, (CH2)p—(CH2CH2O)m-(CH2)n—NR′SO2R″, (CH2)p—(CH2CH2O)m—(CH2)n—COOH, (CH2)p—(CH2CH2O)m—(CH2)n—COOR′, (CH2)p—(CH2CH2O)m—(CH2)n—CONR′R″, (CH2)p-(CH2CH2O)m—(CH2)n—SO2R′, (CH2)p—(CH2CH2O)m—(CH2)n—COR′, (CH2)p—(CH2CH2O)m—(CH2)n—SONR′R″, (CH2)p—(CH2CH2O)m—(CH2)n—SO2NR′R″, Aryl-(CH2)n—COOH, and heteroaryl-alkyl-CO-alkyl-NR′R″m, wherein the alkyl may be substituted with OR′, and heteroaryl-(CH2)n-heterocycle wherein the heterocycle may optionally be substituted with alkyl, hydroxyl, COOR′ and COR′; wherein R′ and R″ are selected from H, alkyl, alkyl substituted with halogen, hydroxyl, NH2, NH(alkyl), N(alkyl)2, oxo, carboxy, clcloalkyl and heteroaryl;
m, n, and p are independently 0 to 6;
R12′ of Formula A-4-1 through A-4-6 is selected from the group consisting of —O-(alkyl), —O-(alkyl)-akoxy, —C(O)-(alkyl), —C(OH)-alkyl-alkoxy, —C(O)—NH-(alkyl), —C(O)—N-(alkyl)2, —S(O)-(alkyl), S(O)2-(alkyl), —C(O)-(cyclic amine), and —O-aryl-(alkyl), —O-aryl-(alkoxy);
R1″ of Formula A-4-1 through A-4-6 is selected from the group consisting of H, alkyl, aryl substituted alkyl, aloxy substituted alkyl, cycloalkyl, ary-substituted cycloalkyl, and alkoxy substituted cycloalkyl; and
denotes connection to L.

### Claim 15 (depends on 13)

The bifunctional compound according to claim 13, wherein the MLM is selected from:

### Claim 16 (depends on 1)

The bifunctional compound according to claim 1, wherein the ULM is a IAP E3 ubiquitin ligase binding moiety (ILM) comprising the amino acids alanine (A), valine (V), proline (P), and isoleucine (I) or their unnatural mimetics.

### Claim 17 (depends on 16)

The bifunctional compound according to claim 16, wherein the ULM is a IAP E3 ubiquitin ligase binding moiety (ILM) comprising a AVPI tetrapeptide fragment or derivative thereof.

### Claim 18 (depends on 16)

The bifunctional compound according to claim 16, the ILM is selected from the group consisting of chemical structures represented by Formulas (I), (II), (III), (IV), and (V):
wherein:
R1 for Formulas (I), (II), (III), (IV), and (V) is selected from H or alkyl;
R2 for Formulas (I), (II), (III), (IV), and (V) is selected from H or alkyl;
R3 for Formulas (I), (II), (III), (IV), and (V) is selected from H, alkyl, cycloalkyl and heterocycloalkyl;
R5 and R6 for Formulas (I), (II), (III), (IV), and (V) are independently selected from H, alkyl, cycloalkyl, heterocycloalkyl, or more preferably, R5 and R6 taken together for Formulas (I), (II), (III), (IV), and (V) form a pyrrolidine or a piperidine ring further optionally fused to 1-2 cycloalkyl, heterocycloalkyl, aryl or heteroaryl rings, each of which can then be further fused to another cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring;
R3 and R5 for Formulas (I), (II), (III), (IV), and (V) taken together can form a 5-8-membered ring further optionally fused to 1-2 cycloalkyl, heterocycloalkyl, aryl or heteroaryl rings;
R7 for Formulas (I), (II), (III), (IV), and (V) is selected from cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aryl-C(O)—R4, arylalkyl, heteroaryl, heteroaryl-C(O)—R4, heteroaryl-R4, heteroaryl-naphthalene, heteroarylalkyl, or —C(O)NH—R4, each one further optionally substituted with 1-3 substituents selected from halogen, alkyl, haloalkyl, hydroxyl, alkoxy, cyano, (hetero)cycloalkyl, aryl, (hetero)aryl, —C(O)NH—R4, or —C(O)—R4; and
R4 is selected from alkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl, aryl or bicyclic aryl, arylalkyl, heteroaryl or bicyclic heteroaryl, heteroarylalkyl, further optionally substituted with 1-3 substituents as described above.

### Claim 19 (depends on 16)

The bifunctional compound according to claim 16, wherein the ILM is selected from the group consisting of:

### Claim 20 (depends on 1)

The bifunctional compound according to claim 1, wherein the linker (L) comprises a chemical structural unit represented by the formula:
-(AL)q-,
wherein:
-(AL)q-is a group which is connected to at least one of ULM, PTM, or both;
q is an integer greater than or equal to 1;
each AL is independently selected from the group consisting of, a bond, CRL1RL2, O, S, SO, SO2, NRL3, SO2NRL3, SONRL3, CONRL3, NRL3CONRL4, NRL3SO2NRL4, CO, CRL1═CRL2, C≡C, SiRL1RL2, P(O)RL1, P(O)ORL1, NRL3C(═NCN)NRL4, NRL3C(═NCN), NRL3C(═CNO2)NRL4, C3-11cycloalkyl optionally substituted with 0-6 RL1 and/or RL2groups, C3-11heteocyclyl optionally substituted with 0-6 RL1 and/or RL2 groups, aryl optionally substituted with 0-6 RL1 and/or RL2 groups, heteroaryl optionally substituted with 0-6 RL1 and/or RL2 groups, where RL1 or RL2, each independently are optionally linked to other groups to form cycloalkyl and/or heterocyclyl moiety, optionally substituted with 0-4 RL5 groups; and
RL1, RL2, RL3, RL4 and RL5 are, each independently, H, halo, C1-8alkyl, OC1-8alkyl, SC1-8alkyl, NHC1-8alkyl, N(C1-8alkyl)2, C3-11cycloalkyl, aryl, heteroaryl, C3-11heterocyclyl, OC1-8cycloalkyl, SC1-8cycloalkyl, NHC1-8cycloalkyl, N(C1-8cycloalkyl)2, N(C1-8cycloalkyl)(C1-8alkyl), OH, NH2, SH, SO2C1-8alkyl, P(O)(OC1-8alkyl)(C1-8alkyl), P(O)(OC1-8alkyl)2, CC—C1-8alkyl, CCH, CH═CH(C1-8alkyl), C(C1-8alkyl)═CH(C1-8alkyl), C(C1-8alkyl)═C(C1-8alkyl)2, Si(OH)3, Si(C1-8alkyl)3, Si(OH)(C1-8alkyl)2, COC1-8alkyl, CO2H, halogen, CN, CF3, CHF2, CH2F, NO2, SF5, SO2NHC1-8alkyl, SO2N(C1-8alkyl)2, SONHC1-8alkyl, SON(C1-8alkyl)2, CONHC1-8alkyl, CON(C1-8alkyl)2, N(C1-8alkyl)CONH(C1-8alkyl), N(C1-8alkyl)CON(C1-8alkyl)2, NHCONH(C1-8alkyl), NHCON(C1-8alkyl)2, NHCONH2, N(C1-8alkyl)SO2NH(C1-8alkyl), N(C1-8alkyl) SO2N(C1-8alkyl)2, NH SO2NH(C1-8alkyl), NH SO2N(C1-8alkyl)2, NH SO2NH2.

### Claim 21 (depends on 1)

The bifunctional compound according to claim 1, wherein L is means for covalently coupling the PTM to the ULM.

### Claim 22 (depends on 1)

The bifunctional compound according to claim 1, wherein the unit AL of linker (L) is selected from the group consisting of:
or
wherein:
*N of the heterocycloalkyl is shared with the PTM; and
each m, n, o, p, q, r, and s are independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20.

### Claim 23 (depends on 1)

The bifunctional compound according to claim 1, wherein the unit AL of linker (L) is selected from the group consisting of:
wherein N* of the heterocycloalkyl is shared with the PTM.

### Claim 24 (depends on 1)

The bifunctional compound according to claim 1, wherein the linker (L) is a polyethylenoxy group optionally substituted with aryl or phenyl comprising from 1 to 10 ethylene glycol units.

### Claim 25 (depends on 1)

The bifunctional compound according to claim 1, wherein the linker is an optionally substituted C1-C50 alkyl, wherein each carbon is optionally substituted with (1) a heteroatom selected from N, S, P, or Si atoms that has an appropriate number of hydrogens, substitutions, or both to complete valency, (2) an optionally substituted cycloalkyl or bicyclic cycloalkly, (3) an optionally substituted heterocyloalkyl or bicyclic heterocyloalkyl, (4) an optionally substituted aryl bicyclic aryl, or (5) optionally substituted heteroaryl or bicyclic heteroaryl, with the proviso that there is no heteroatom-heteroatom bonding (e.g., no heteroatoms are covalently linked or adjacently located).

### Claim 26 (depends on 1)

The bifunctional compound according to claim 1, wherein the linker (L) comprises the following chemical structure:
wherein:
WL1 and WL2 are each independently absent, a 4-8 membered ring with 0-4 heteroatoms, optionally substituted with RQ, each RQ is independently a H, halo, OH, CN, CF3, optionally substituted linear or branched C1-C6 alkyl, optionally substituted linear or branched C1-C6 alkoxy, or 2 RQ groups taken together with the atom they are attached to, form a 4-8 membered ring system containing 0-4 heteroatoms;
YL1 is each independently a bond, optionally substituted linear or branched C1-C6 alkyl and optionally one or more C atoms are replaced with O; or optionally substituted linear or branched C1-C6 alkoxy;
n is 0-10; and
indicates the attachment point to the PTM or ULM moieties.

### Claim 27 (depends on 1)

The bifunctional compound according to claim 1, wherein the linker (L) comprises the following chemical structure:
wherein:
WL1 and WL2 are each independently absent, aryl, heteroaryl, cyclic, heterocyclic, C1-6 alkyl and optionally one or more C atoms are replaced with O or N, C1-6 alkene and optionally one or more C atoms are replaced with O, C1-6 alkyne and optionally one or more C atoms are replaced with O, bicyclic, biaryl, biheteroaryl, or biheterocyclic, each optionally substituted with RQ, each RQ is independently a H, halo, OH, CN, CF3, hydroxyl, nitro, C≡CH, C2-6 alkenyl, C2-6 alkynyl, optionally substituted linear or branched C1-C6 alkyl, optionally substituted linear or branched C1-C6 alkoxy, optionally substituted OC1-3alkyl (e.g., optionally substituted by 1 or more —F), OH, NH2, NRY1RY2, CN, or 2 RQ groups taken together with the atom they are attached to, form a 4-8 membered ring system containing 0-4 heteroatoms;
YL1 is each independently a bond, NRYL1, O, S, NRYL2, CRYL1RYL2, C═O, C═S, SO, SO2, optionally substituted linear or branched C1-C6 alkyl and optionally one or more C atoms are replaced with O; optionally substituted linear or branched C1-C6 alkoxy (linear, branched, optionally substituted), 3-6 membered alicyclic or aromatic ring with 0-4 heteroatoms;
QL is a 3-6 membered alicyclic or aromatic ring with 0-4 heteroatoms, optionally bridged, optionally substituted with 0-6 RQ, each RQ is independently H, C1-6 alkyl (linear, branched, optionally substituted by 1 or more halo, C1-6 alkoxyl), or 2 RQ groups taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms);
RYL1, RYL2 are each independently H, OH, linear or branched C1-6 alkyl optionally substituted by 1 or more halo or C1-6 alkoxyl, or R1, R2 together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms;
n is 0-10; and
indicates the attachment point to the PTM or ULM moieties.

### Claim 28 (depends on 1)

The bifunctional compound according to claim 1, wherein at least one of:
(a) the PTM is selected from a compound of Table 4, 6, 8, 10 or 12, or a PTM of Table 1;
(b) the ULM is selected from a compound of Tables 4, 6, 8, 10, and 12 or a ULM of Table 3;
(c) the unit AL of linker (L) is selected from a compound of Tables 4, 6, 8, 10 and, or a L from Table 2; or
(d) combinations thereof.

### Claim 29 (depends on 1)

The bifunctional compound of claim 1, wherein the compound is selected from the group consisting of: exemplary compounds 1-249, 254-454, and 458-573.

### Claim 30 (depends on 1)

A composition comprising an effective amount of a bifunctional compound of claim 1, and a pharmaceutically acceptable carrier.

### Claim 31 (depends on 1, 30)

The composition of claim 30, wherein the composition further comprises at least one of additional bioactive agent or another bifunctional compound of claim 1.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the additional bioactive agent is an anti-cancer agent.

### Claim 33 (depends on 1)

A method for treating a disease or disorder in a subject, the method comprising administering a composition comprising a pharmaceutically acceptable carrier and an effective amount of at least one compound of claim 1 to a subject in need thereof, wherein the compound is effective in treating or ameliorating at least one symptom of the disease or disorder.

### Claim 34 (depends on 33)

The method according to claim 33, wherein the disease or disorder is associated with at least one of accumulation, aggregation, overactivation, or combinations thereof, of KRas.

### Claim 35 (depends on 33)

The method according to claim 33, wherein the disease or disorder is cancer that is associated with the accumulation, aggregation, and/or overactivation of KRas.

### Claim 36 (depends on 34)

The method according to claim 34, wherein the disease or disorder is pancreatic cancer, colon cancer, colorectal cancer, lung cancer, non-small cell lung cancer, biliary tract malignancies, endometrial cancer, cervical cancer, bladder cancer, liver cancer, myeloid leukemia, and breast cancer.

### Claim 37 (depends on 34)

The method according to claim 34, wherein the disease or disorder is pancreatic cancer, colon cancer, lung cancer, non-small cell lung cancer.
